Table 3 Trends in the products transfused during massive transfusion within the first 2Â days of admission
Procedures* | Calendar year | P for trend | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | ||
RBCs, unit, mean | 32.1 | 31.3 | 32.1 | 30.5 | 31.6 | 31.7 | 32.7 | 31.9 | 32.8 | 31.8 | 0.33 |
FFP, unit, mean | 26.4 | 26.6 | 27.7 | 27.3 | 29.4 | 31.4 | 32.8 | 33.1 | 35.4 | 34.7 | < 0.001 |
Platelets, unit, mean | 22.2 | 23.1 | 24.2 | 24.1 | 26.3 | 27.0 | 27.2 | 25.5 | 26.3 | 25.0 | 0.040 |
FFP-to-RBC ratio, median | 0.77 | 0.83 | 0.83 | 0.86 | 0.90 | 1.00 | 1.00 | 1.00 | 1.00 | 1.08 | < 0.001 |
Platelet-to-RBC ratio, median | 0.71 | 0.77 | 0.77 | 0.77 | 0.83 | 0.83 | 0.83 | 0.79 | 0.83 | 0.78 | 0.060 |
Crystalloid, L, median | 13.7 | 13.8 | 13.1 | 13.6 | 13.2 | 13.2 | 13.1 | 13.3 | 12.2 | 12.5 | 0.031 |
Tranexamic acid, % | 44.0 | 48.7 | 52.3 | 54.2 | 62.2 | 62.6 | 64.8 | 67.5 | 65.3 | 73.6 | < 0.001 |
Fibrinogen concentrate, % | 1.3 | 2.7 | 5.3 | 3.4 | 4.4 | 4.1 | 5.4 | 5.6 | 8.2 | 12.1 | < 0.001 |
Recombinant factor VIIa, % | 0.6 | 1.7 | 1.7 | 1.2 | 0.7 | 0.9 | 0.8 | 0.4 | 0.6 | 0.8 | 0.087 |
Cryoprecipitate, % | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.4 | < 0.001 |